产前 perfluorine 和多基物质 (PFAS) 暴露与婴儿神经发育之间的关系:修改DHA修改效应的修订版
Ting-Ting Jiang1, Lian-Man Lei1, Xia-Yu Zhang1
1Department of Maternal, Child & Adolescent Health, School of Public Health, Anhui Medical University, Hefei, Anhui Province, China.
Ecotoxicology and environmental safety
|June 24, 2025
概括
产前暴露于per-和多基基物质 (PFAS) 与婴儿发育延迟有关,特别是在女孩身上. 产后补充多可沙赫萨酸 (DHA) 可以帮助减轻这些影响.
科学领域:
- 环境健康 环境健康
- 神经发育儿科 神经发育儿科
- 毒理学 毒理学 毒理学
背景情况:
- 产前暴露于和多基基物质 (PFAS) 是对婴儿神经发育的日益关注的问题.
- 补充多可萨赫萨酸 (DHA) 显示了改善神经发育的潜力.
- 关于DHA在抵消PFAS诱导的神经发育延迟方面的有效性,目前的研究有限.
研究的目的:
- 调查产前PFAS暴露与婴儿神经发育迟缓之间的关联.
- 在暴露于PFAS的背景下,评估产后DHA补充对婴儿神经发育的影响.
主要方法:
- 这项研究涉及来自中国WuHu出生队列研究 (WH-BC) 的2415对母婴.
- 使用液态染色体质谱法 (LC-MS/MS) 分析了6种常见的PFAS.
- 婴儿神经发育在6个月和12个月使用年龄和阶段问卷 (ASQ-3) 进行评估,并使用包括GLM,BKMR和GEE在内的统计分析.
主要成果:
- 产前暴露于特定的PFAS (PFOA,PFNA,PFBS) 与6个月和12个月的发育延迟有显著的关联,在第一和第二个三个月的临界暴露窗口.
- 产前PFAS暴露显示出性别特异性影响,影响男孩的精细运动技能和女孩的沟通/粗运动技能.
- 产后的DHA补充剂减轻了与产前PFAS暴露相关的神经发育延迟的风险.
结论:
- 产前 PFAS 暴露与婴儿发育迟缓有关,在女性婴儿中观察到更高的脆弱性.
- 产后的DHA补充可以缓解产前PFAS暴露引起的婴儿神经发育延迟.
- 调查结果表明,潜在的公共卫生策略可以减轻PFAS对儿童发育的影响.
相关概念视频
Teratogenicity
2.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Attention-Deficit/Hyperactivity Disorder
313
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
313


